A new mini review was published in Oncotarget's Volume 15 on September 30, 2024, entitled, "Linking FOXM1 and PD-L1 to CDK4/6 ...

We suggest that future therapeutic strategies targeting the oncogenic network of CDK4/6, MEK, PD-L1, and FOXM1 represent ...

9 月已经结束。根据 Insight 数据库，有 9 款为抗肿瘤新药在九月向 CDE 递交了上市申请，包括 4 个新药的首次 NDA 和 5 款新药的新适应症/新剂型 NDA，适应症涉及鼻咽癌、大 B ...

Immune checkpoint inhibitors industry is projected to witness a CAGR of 16.7% during the period 2024-2032. This growth can be ...

经济观察网 记者 瞿依贤 北京时间9月27日，美国食品药品监督管理局（FDA）肿瘤药物专家咨询委员会（ODAC）的一场会议结束，历时9个小时。这场会议的讨论结果可能让国内外的PD-1类药物市场大变。

They could have received up to one prior systemic treatment as long as it was not an anti–CTLA-4, PD-1, PD-L1, or PD-L1 agent ...

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a ...

The retrospective study presented at ESMO 2024 involved about 2,400 patients with stage 3 or 4 non-small cell lung cancer.

智通财经APP讯，康方生物(09926)发布公告，中华人民共和国国家药品监督管理局(NMPA)官网系统显示，公司自主研发的全球首创肿瘤免疫治疗药物双特异性抗体开坦尼(卡度尼利，PD-1/CTLA-4)的一项新适应症上市申请(sNDA)的状态更新为“制 ...

Northwestern Medicine scientists have developed a more effective method of delivering a cutting-edge cancer treatment, ...

荷兰乌特勒支 - 临床阶段肿瘤公司Merus N.V. (NASDAQ:MRUS)宣布启动一项3期临床试验，研究新型癌症治疗药物petosemtamab与pembrolizumab联合用于复发或转移性头颈部鳞状细胞癌(r/m HNSCC)患者的治疗。LiGeR-HN1试验已完成首例患者给药，该试验将比较这种联合疗法与单独使用pembrolizumab作为一线治疗的疗效和安全性。 Petosemta ...

After hours of company pushback, FDA's Oncologic Drugs Advisory Committee voted that the benefit of immunotherapy in low or ...